2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 569

Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
Abstract Number: 506

Clinical and Sonographic Characteristics of Carotid Intima-Media Thickness in Rheumatoid Arthritis Patients
Abstract Number: 793

Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis
Abstract Number: 2725

Clinical Characteristics and Long-Term Follow-up of 382 Microscopic Polyangiitis Patients
Abstract Number: 731

Clinical Characteristics and Neurophysiological Patterns of Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
Abstract Number: 947

Clinical Characteristics and Outcome after Treatment of a National Cohort of PCR-Positive Lyme Arthritis
Abstract Number: 2731

Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital
Abstract Number: 469

Clinical Characteristics and Treatment of 25 Children with Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy in China
Abstract Number: 1306

Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)
Abstract Number: 2589

Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 2217

Clinical Characteristics of Early Onset Gout in Outpatient Setting
Abstract Number: 834

Clinical Characteristics of IgA Vasculitis in Children and Adults: A Retrospective Cohort Study
Abstract Number: 1809

Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
Abstract Number: 687

Clinical Characteristics of Spondyloarthritis Patients in Japan in Comparison to Other Regions of the World
Abstract Number: 350

Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].